|
1
|
Akira S, Uematsu S and Takeuchi O:
Pathogen recognition and innate immunity. Cell. 124:783–801. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Takeda K, Kaisho T and Akira S: Toll-like
receptors. Annu Rev Immunol. 21:335–376. 2003. View Article : Google Scholar
|
|
3
|
Yu L and Chen S: Toll-like receptors
expressed in tumor cells: targets for therapy. Cancer Immunol
Immunother. 57:1271–1278. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Medzhitov R, Preston-Hurlburt P and
Janeway CA Jr: A human homologue of the Drosophila Toll protein
signals activation of adaptive immunity. Nature. 388:394–397. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Poltorak A, He X, Smirnova I, et al:
Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations
in Tlr4 gene. Science. 282:2085–2088. 1998. View Article : Google Scholar
|
|
6
|
Pathak SK, Basu S, Bhattacharyya A, Pathak
S, Kundu M and Basu J: Mycobacterium tuberculosis
lipoarabinomannan-mediated IRAK-M induction negatively regulates
Toll-like receptor-dependent interleukin-12 p40 production in
macrophages. J Biol Chem. 280:42794–42800. 2005. View Article : Google Scholar
|
|
7
|
He W, Liu Q, Wang L, Chen W, Li N and Cao
X: TLR4 signaling promotes immune escape of human lung cancer cells
by inducing immunosuppressive cytokines and apoptosis resistance.
Mol Immunol. 44:2850–2859. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fallows S, Price J, Atkinson RJ, Johnston
PG, Hickey I and Russell SE: P53 mutation does not affect prognosis
in ovarian epithelial malignancies. J Pathol. 194:68–75. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Byrd-Leifer CA, Block EF, Takeda K, Akira
S and Ding A: The role of MyD88 and TLR4 in the LPS-mimetic
activity of Taxol. Eur J Immunol. 31:2448–2457. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lord KA, Hoffman-Liebermann B and
Liebermann DA: Nucleotide sequence and expression of a cDNA
encoding MyD88, a novel myeloid differentiation primary response
gene induced by IL6. Oncogene. 5:1095–1097. 1990.
|
|
11
|
Asschert JG, Vellenga E, Ruiters MH and de
Vries EG: Regulation of spontaneous and TNF/IFN-induced IL-6
expression in two human ovarian-carcinoma cell lines. Int J Cancer.
82:244–249. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Watson JM, Sensintaffar JL, Berek JS and
Martinez-Maza O: Constitutive production of interleukin 6 by
ovarian cancer cell lines and by primary ovarian tumor cultures.
Cancer Res. 50:6959–6965. 1990.
|
|
13
|
Wu S, Rodabaugh K, Martinez-Maza O, et al:
Stimulation of ovarian tumor cell proliferation with monocyte
products inducing interleukin 1, interleukin 6 and tumor necrosis
factor-alpha. Am J Obstet Gynecol. 166:977–1007. 1992.PubMed/NCBI
|
|
14
|
Obata NH, Tamakoshi K, Shibata K, Kikkawa
F and Tomoda Y: Effects of interleukin-6 on in vitro cell
attachment, migration and invasion of human ovarian carcinoma.
Anticancer Res. 17:337–342. 1997.PubMed/NCBI
|
|
15
|
Nilsson MB, Langley RR and Fidler IJ:
Interleukin-6, secreted by human ovarian carcinoma cells, is a
potent proangiogenic cytokine. Cancer Res. 65:10794–10800. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shahzad MM, Arevalo JM, Armaiz-Pena GN, et
al: Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian
cancer growth and metastasis. J Biol Chem. 285:35462–35470. 2010.
View Article : Google Scholar
|
|
17
|
Kawai T, Adachi O, Ogawa T, Takeda K and
Akira S: Unresponsiveness of MyD88-deficient mice to endotoxin.
Immunity. 11:115–122. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Björkbacka H, Fitzgerald KA, Huet F, et
al: The induction of macrophage gene expression by LPS
predominantly utilizes Myd88-independent signaling cascades.
Physiol Genomics. 19:319–330. 2004.PubMed/NCBI
|
|
19
|
Kelly MG, Alvero AB, Chen R, et al: TLR-4
signaling promotes tumor growth and Pac chemoresistance in ovarian
cancer. Cancer Res. 66:3859–3868. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang AC, Su QB, Wu FX, Zhang XL and Liu
PS: Role of TLR4 for Pac chemotherapy in human epithelial ovarian
cancer cells. Eur J Clin Invest. 39:157–164. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mao HL, Liu PS, Zheng JF, et al:
Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells
to TRAIL or Pac-induced apoptosis in vitro. Pharmacol Res.
56:483–492. 2007. View Article : Google Scholar
|
|
22
|
Wani MC, Taylor HL, Wall ME, Coggon P and
McPhail AT: Plant antitumor agents. VI The isolation and structure
of taxol, a novel antileukemic and antitumor agent from Taxus
brevifolia. J Am Chem Soc. 93:2325–2327. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Manfredi JJ, Parness J and Horwitz SB:
Taxol binds to cellular microtubules. J Cell Biol. 94:688–696.
1982. View Article : Google Scholar
|
|
24
|
Wang J, Kobayashi M, Han M, et al: MyD88
is involved in thesignalling pathway for Taxol-induced apoptosis
and TNF-alpha expression in human myelomonocytic cells. Br J
Haematol. 118:638–645. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zimmer SM, Liu J, Clayton JL, Stephens DS
and Snyder JP: Paclitaxelbinding to human and murine MD-2. J Biol
Chem. 283:27916–27926. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ozols RF, Bundy BN, Greer BE, et al: Phase
III trial of carboplatin and Paclitaxel compared with cisplatin and
Pac in patients with optimally resected stage III ovarian cancer: a
Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003.
View Article : Google Scholar
|
|
27
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ding AH, Porteu F, Sanchez E and Nathan
CF: Shared actions of endotoxin and taxol on TNF receptors and TNF
release. Science. 248:370–372. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brint EK, Xu D, Liu H, et al: ST2 is an
inhibitor of interleukin 1 receptor and Toll-like receptor 4
signaling and maintains endotoxin tolerance. Nat Immunol.
5:373–379. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Burns K, Janssens S, Brissoni B, Olivos N,
Beyaert R and Tschopp J: Inhibition of interleukin 1
receptor/Toll-like receptor signaling through the alternatively
spliced, short form of MyD88 is due to its failure to recruit
IRAK-4. J Exp Med. 197:263–268. 2003. View Article : Google Scholar
|
|
31
|
Schmitz I, Kirchhoff S and Krammer PH:
Regulation of death receptor-mediated apoptosis pathways. Int J
Biochem Cell Biol. 32:1123–1136. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang B, Zhao J, Li H, et al: Toll-like
receptors on tumor cells facilitate evasion of immune surveillance.
Cancer Res. 65:5009–5014. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pérez-Tomás R: Multidrug resistance:
retrospect and prospects in anti-cancer drug treatment. Curr Med
Chem. 13:1859–1876. 2006.PubMed/NCBI
|
|
34
|
Fulda S and Debatin KM: Extrinsic versus
intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nakanishi C and Toi M: Nuclear
factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat
Rev Cancer. 5:297–309. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Silasi DA, Alvero AB, Illuzzi J, et al:
MyD88 predicts chemoresistance to Pac in epithelial ovarian cancer.
Yale J Biol Med. 79:153–163. 2006.PubMed/NCBI
|
